Cath Vision Aps
CathVision is dedicated to advancing electrophysiology (EP) recording technologies to improve the diagnosis and treatment of cardiac arrhythmias. Their mission is to empower physicians with innovative solutions, including high-fidelity EP recording systems and AI-based analytic tools, to enhance clinical decision-making and patient outcomes. Since its inception in Denmark in 2013, the company has expanded to the U.S. and is focused on developing and commercializing its ECGenius™ System and CARDIALYTICS™ suite of AI algorithms.
Industries
Nr. of Employees
small (1-50)
Cath Vision Aps
Lygten 37 st. th. 2400 Copenhagen NV, Denmark
Patents
Products
High-fidelity electrophysiology recording system
A multi-channel EP recording platform that acquires low-noise unipolar and bipolar electrograms and surface ECGs to improve visualization of low-amplitude cardiac signals during ablation procedures.
AI-based electrogram analytics suite
A suite of real-time analytical algorithms for automated electrogram interpretation and procedural decision support, including modules for pulmonary vein isolation detection, signal complexity quantification, focal source classification, and post-ablation energy assessment.
High-fidelity electrophysiology recording system
A multi-channel EP recording platform that acquires low-noise unipolar and bipolar electrograms and surface ECGs to improve visualization of low-amplitude cardiac signals during ablation procedures.
AI-based electrogram analytics suite
A suite of real-time analytical algorithms for automated electrogram interpretation and procedural decision support, including modules for pulmonary vein isolation detection, signal complexity quantification, focal source classification, and post-ablation energy assessment.
Services
Collaboration with hospitals and academic centers to run multicenter and single-site clinical studies validating signal acquisition and analytic algorithms for electrophysiology procedures.
Clinical evaluation visits to assess system performance in EP labs and provide deployment assistance and training to clinical staff.
Technical support channels for deployed systems with stated response times for weekday inquiries.
Collaboration with hospitals and academic centers to run multicenter and single-site clinical studies validating signal acquisition and analytic algorithms for electrophysiology procedures.
Clinical evaluation visits to assess system performance in EP labs and provide deployment assistance and training to clinical staff.
Technical support channels for deployed systems with stated response times for weekday inquiries.
Expertise Areas
- Electrophysiology device development
- AI-driven electrogram analytics
- Clinical trial management for medical devices
- Medical device regulatory compliance and quality systems
Key Technologies
- High-fidelity multi-channel intracardiac signal acquisition
- Low-noise amplifier architecture
- Unipolar and bipolar electrogram acquisition
- AI/ML algorithms for electrogram interpretation
News & Updates
CathVision announces a financing round of $9 million to help advance commercial operations driving adoption of the ECGenius™ System, and to support the continued development of AI-powered analytic modules.
CathVision announces FDA clearance of the ECGenius™ System, setting a new standard for ECG signal acquisition, interpretation, and therapy support.
CathVision announces the market release of ECGenius™ System Version 3.4, with software enhancements to improve procedural workflow and physician usability.
Development of PFAnalyzer, a new algorithmic tool to assess durable lesion during Pulsed Field Ablation, enhancing the electrophysiology software portfolio.
The ECGenius™ System received FDA clearance, establishing it as a high-fidelity, low-noise EP recording technology.
CathVision announces a financing round of $9 million to help advance commercial operations driving adoption of the ECGenius™ System, and to support the continued development of AI-powered analytic modules.
CathVision announces FDA clearance of the ECGenius™ System, setting a new standard for ECG signal acquisition, interpretation, and therapy support.
CathVision announces the market release of ECGenius™ System Version 3.4, with software enhancements to improve procedural workflow and physician usability.
Development of PFAnalyzer, a new algorithmic tool to assess durable lesion during Pulsed Field Ablation, enhancing the electrophysiology software portfolio.
The ECGenius™ System received FDA clearance, establishing it as a high-fidelity, low-noise EP recording technology.